APA (7th ed.) Citation

Park, S. J., Cerella, C., Kang, J. M., Byun, J., Kum, D., Orlikova-Boyer, B., . . . Diederich, M. (2025). Tetrahydrobenzimidazole TMQ0153 targets OPA1 and restores drug sensitivity in AML via ROS-induced mitochondrial metabolic reprogramming. Journal of Experimental & Clinical Cancer Research (17569966), 44(1), 1. https://doi.org/10.1186/s13046-025-03372-0

Chicago Style (17th ed.) Citation

Park, Su Jung, et al. "Tetrahydrobenzimidazole TMQ0153 Targets OPA1 and Restores Drug Sensitivity in AML via ROS-induced Mitochondrial Metabolic Reprogramming." Journal of Experimental & Clinical Cancer Research (17569966) 44, no. 1 (2025): 1. https://doi.org/10.1186/s13046-025-03372-0.

MLA (9th ed.) Citation

Park, Su Jung, et al. "Tetrahydrobenzimidazole TMQ0153 Targets OPA1 and Restores Drug Sensitivity in AML via ROS-induced Mitochondrial Metabolic Reprogramming." Journal of Experimental & Clinical Cancer Research (17569966), vol. 44, no. 1, 2025, p. 1, https://doi.org/10.1186/s13046-025-03372-0.